glp-1 vomiting and diarrhea Overdose risks increase as demand for injectable weight-loss drugs on the rise, research finds Adverse effects of GLP-1 class
Description
Specific to cardiovascular-related death, ELIXA and SUSTAIN-6 trials showed similar performance relative to the placebo [ HR = 0.98 (95% CI 0.781.22) and HR = 0.98 (95% CI 0.651.48), respectively]
The culture was harvested by centrifugation for 48 h post-infection and cell pellets were stored at 80 C until use
doi: 10.1111/dom.14496 48 ChavdaVPAjabiyaJTeliDBojarskaJApostolopoulosV
p = 0.001) (Supplementary Table 2)
In these very high-risk patients, SGLT-2 inhibitors reduce overall mortality with a number needed to treat (NNT) of 25 (95% CI, 18 to 48) over five years
